JSF Financial LLC Purchases Shares of 17,500 ALX Oncology Holdings Inc. (NASDAQ:ALXO)

JSF Financial LLC acquired a new stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 17,500 shares of the company’s stock, valued at approximately $29,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. AQR Capital Management LLC boosted its position in ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after buying an additional 6,080 shares during the period. SG Americas Securities LLC grew its position in ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after acquiring an additional 6,888 shares during the last quarter. Privium Fund Management B.V. increased its stake in ALX Oncology by 28.2% in the 3rd quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock worth $926,000 after purchasing an additional 112,093 shares during the period. Los Angeles Capital Management LLC bought a new stake in ALX Oncology in the third quarter valued at approximately $469,000. Finally, GSA Capital Partners LLP bought a new position in shares of ALX Oncology in the third quarter worth approximately $88,000. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Trading Down 4.6 %

ALXO opened at $1.04 on Tuesday. The stock has a market cap of $54.85 million, a PE ratio of -0.35 and a beta of 0.96. The business has a 50 day moving average of $1.61 and a 200-day moving average of $1.93. ALX Oncology Holdings Inc. has a 52 week low of $1.03 and a 52 week high of $17.83. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Insider Transactions at ALX Oncology

In other news, Director Rekha Hemrajani bought 30,000 shares of the stock in a transaction on Monday, December 2nd. The shares were bought at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the acquisition, the director now owns 33,000 shares in the company, valued at $51,150. The trade was a 1,000.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 14,443 shares of company stock valued at $23,309 in the last quarter. 33.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ALXO has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. UBS Group dropped their price objective on ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a report on Monday, January 27th. Jefferies Financial Group downgraded ALX Oncology from a “buy” rating to a “hold” rating and decreased their target price for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Finally, HC Wainwright dropped their price target on ALX Oncology from $25.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, January 24th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, ALX Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $3.05.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.